Lasa Supergenerics Limited (LASA.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹5.03 (+0.00%) as of
Key statistics
- Market cap
- 252.01M
- EPS (TTM)
- -0.80
- Dividend yield
- 0.00%
- 52-week range
- 5.03 – 12.46
- Beta
- 0.64
- Revenue (TTM)
- 65.2M
- Profit margin
- -253.84%
- Volume
- 1.00
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Ratnagiri, India
- Employees
- 9
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.